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Platelets: No Longer Bystanders
in Liver Disease
Abhishek Chauhan,1 David H. Adams,1 Steve P. Watson,2 and Patricia F. Lalor1
Growing lines of evidence recognize platelets as central players in liver homeostasis and pathobiology. Platelets have
important roles at every stage during the continuum of liver injury and healing. These cells contribute to the initiation
of liver inﬂammation by promoting leukocyte recruitment through sinusoidal endothelium. They can activate effector
cells, thus amplifying liver damage, and by modifying the hepatic cellular and cytokine milieu drive both hepatoprotec-
tive and hepatotoxic processes. Conclusion: In this review we summarize how platelets drive such pleiotropic actions
and attempt to reconcile the paradox of platelets being both deleterious and beneﬁcial to liver function; with increas-
ingly novel methods of manipulating platelet function at our disposal, we highlight avenues for future therapeutic
intervention in liver disease. (HEPATOLOGY 2016; 00:000–000)
Traditional paradigms of platelet function focuson the role of platelets in mediating hemosta-sis at points of endothelial disruption or vascu-
lar damage. The archetypal platelet role, starting from
adhesion to the damaged vessel wall followed by acti-
vation and aggregation triggering the clotting cascade,
has been well described; and antiplatelet therapy block-
ing one or multiple points of the above sequence is the
cornerstone of pharmacological therapy aimed at pre-
venting arteriothrombotic vasculo-occlusive events.
However, antiplatelet therapy is often halted or sus-
pended in patients with chronic liver disease due to the
association with a coagulopathy. The relatively com-
mon occurrence of portal venous thrombosis in
patients with cirrhosis argues against such a strategy,
and it is likely that the bleeding diathesis associated
with chronic liver disease is overstated.(1,2) Conse-
quently, little is known about the effects of antiplatelet
therapy in liver disease.
A growing body of evidence derived from rodent
and in vitro studies highlights a role for platelets far
beyond the conﬁnes of hemostasis as active players in
liver inﬂammation (Tables 1 and 2).(3,4) Platelets enter
the injured liver and interact with hepatic sinusoidal
endothelium, inﬂuencing effector cell recruitment and
activation.(5) These cellular interactions can result in
the release of a range of up to 300 bioactive proteins
(including cytokines, chemokines, growth factors,
hemostatic proteins, and bacteriocidal agents(6)) from
platelet a-granules as well as bioactive lipids such as
sphingosine 1-phosphate. By releasing these bioactive
molecules platelets are able to drive diverse hepatic
processes ranging from necroinﬂammation and ﬁbrosis
to liver repair and regeneration (Table 2).(3) Inﬂamma-
tory reactions are multistep processes that can be either
acute or chronic, and their sequence can vary greatly
depending on the situation and organ concerned.(7)
Platelets contribute to hepatic inﬂammation in a
Abbreviations: CCL, chemokine (C-C motif) ligand; CD, cluster of differentiation; CTL, cytotoxic T lymphocyte; CXCL, chemokine (C-X-C motif)
ligand; HGF, hepatocyte growth factor; HSC, hepatic stellate cell; HSEC, hepatic sinusoidal endothelial cell; 5HT, 5-hydroxytryptamine; IL-6, inter-
leukin-6; NAFLD, nonalcoholic fatty liver disease; PDGF, platelet-derived growth factor; TGF-b, transforming growth factor-b; TNF-a, tumor
necrosis factor-a; VEGF, vascular endothelial growth factor.
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disease-speciﬁc, stage-speciﬁc, and site-speciﬁc man-
ner; and it is this variance that helps to explain the
pleiotropic effects of platelets in liver disease. When
studying the role of platelets in liver disease, strategies
employed to block platelet activation can be highly
platelet-speciﬁc (low-dose aspirin, clopidogrel, and
platelet depletion) or can also affect other cell types
(cilostizol, rho kinase inhibitors, and protease-
activated receptor blockade). The latter must be taken
into account when deﬁning a role for platelets in liver
disease and may explain discrepancies in the observed
platelet effect in models of liver damage (see below).
Max Schultz, who ﬁrst described platelets in 1865
stated, “to those who are concerned with the in-depth
study of the blood of humans, the study of these cells
is enthusiastically recommended.”(8) His statement
remains as pertinent as ever, particularly in a hepatic
context. We are only beginning to elucidate the com-
plex roles these cells play in maintaining liver health
and driving liver disease.
The Interaction Between
Platelets and Liver
Sinusoidal Endothelium
Regulates Hepatic
Leukocyte Inﬁltration
Hepatic sinusoids are lined by unique fenestrated
endothelial cells, which are exposed to only minimal
shear stress(5) and have scavenger-like functions.(9)
The unique phenotype of sinusoidal endothelium char-
acterized by a paucity of P-selectin expression (both
constitutive and inﬂammation-induced) and low levels
of von Willebrand factor(5) helps to set the hepatic vas-
culature apart from the majority of other endothelial
beds, thus rendering the liver a specialized environ-
ment for platelet-endothelial interactions. The combi-
nations of signals which govern recruitment of
TABLE 1. Summary of Models Discussed
Type of model/injury Species Intervention In vivo or in vitro
Effect of intervention
on liver Reference
Viral hepatitis Mouse Platelet depletion In vivo Hepatoprotective 47
Viral hepatitis Mouse Inhibition of platelet
activation
In vitro and in vivo Hepatoprotective 12,13,48-51
Viral hepatitis Mouse Blocking platelet binding
to endothelium
In vitro and in vivo Variable can be either
hepatoprotective or
hepatotoxic
5,12
Isolated HSEC coculture
with platelets
Human Blocking platelet binding
to endothelium
In vitro Hepatoprotective
(reduced effector cell
recruitment)
5
Ischemia-reperfusion Mouse Blocking platelet-Kupffer
cell interaction
In vivo Hepatoprotective (reduc-
tion in steatosis)
42,45,46
Thermal injury Mouse Blocking platelet binding In vivo Hepatotoxic (reduced
neutrophil-mediated
repair)
30
Acute cholestasis Mouse Inhibition of platelet
activation
In vivo Hepatoprotective 58-60
Chronic cholestasis Mouse Platelet depletion/inhibi-
tion of platelet activation
In vivo Hepatotoxic (worsens
fibrosis)
62,63
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immune cells across the sinusoidal bed are distinct
from those reported in other solid organs,(5,10) and pla-
telets may compensate for the lack of expression of
attachment factors such as selectins(10) to assist in leu-
kocyte recruitment during inﬂammation. Studies in
viral models of murine hepatitis,(11-13) human liver
regeneration, and ischemia-reperfusion injury(14) dem-
onstrate platelet sequestration within hepatic sinusoids.
In vitro studies with human hepatic sinusoidal endo-
thelial cells (HSECs) demonstrate that platelet adhe-
sion is partly integrin (GPIIb/IIIa and aVb3)-
mediated,(5) with the precise location of hepatic plate-
let adhesion varying dependent on the type of injury.
For instance in ischemia-reperfusion injury platelets
are selectively sequestered to the periportal and midzo-
nal sinusoidal endothelium.(5) Bound platelets activate
isolated HSECs to express chemokine (C-X-C motif)
ligand 8 (CXCL-8) and chemokine (C-C motif)
ligand 2 (CCL-2), thereby promoting neutrophil and
lymphocyte recruitment (Fig. 1).(5) Studies in rats have
revealed that platelet-driven leukocyte recruitment
results in hepatic damage during systemic endotoxemia
and that platelet-endothelial interactions precede and
drive leukocyte adherence.(15) Furthermore, leukocytes
themselves can also recruit platelets to the liver. Mod-
els of ischemia-reperfusion injury in mice reveal the
ability of cluster of differentiation 4 (CD4) T cells to
activate endothelial cells, thus driving platelet recruit-
ment to the liver sinusoids (Fig. 1). The end result is a
self-perpetuating cycle of microvascular dysfunction
and hepatocellular injury.(16) A schematic summarizing
platelet HSECs and lymphocyte interactions is shown
in Fig. 1.
Platelet Interactions With
Myeloid Cells
Platelet interaction with myeloid cells, particularly
macrophages and neutrophils, has been extensively
investigated in the context of cardiovascular disease,
thrombosis, and atherosclerosis.(17-19) The role plate-
lets play in innate immunity and inﬂammation through
interaction with myeloid cells is, however, frequently
overlooked.(20) These inﬂammatory and immune inter-
actions are highly relevant to liver disease because neu-
trophils and macrophages play central roles in liver
injury, ﬁbrogenesis, and regeneration.(21-24)
In both humans and mice, neutrophils are recruited
and activated during the acute phase of liver inﬂamma-
tion in response to a variety of injuries.(24,25) Choles-
tatic liver injury,(26) alcoholic hepatitis,(23,27) drug-
induced injury,(28) and chemical-induced injury(29) are
TABLE 2. Summary of the Various Platelet-Derived Mediator Effects in the Liver
Context
(type/stage
of liver injury)
Platelet-derived
cytokine (if any)
involved
Cell(s)/structure(s)
involved
Effect on
cell/structure
Overall effect
on liver Reference
Resection HGF, VEGF,
insulin-like
growth factor-1
Hepatocyte Phosphorylation of Akt
and extracellular
signal-regulated
kinases 1/2
Liver regeneration 65,68,69,71
Resection Sphingosine
1-phosphate
Liver sinusoidal
endothelial cells
Liver sinusoidal endothe-
lial cells start to pro-
duce IL-6 and VEGF
Liver regeneration 68,69
Resection Direct Kupffer
cell adherence
Kupffer cell Kupffer cells produce
TNF-a and IL-6
Liver regeneration 70,71
Hepatectomy Serotonin Hepatocyte Hepatocyte proliferation Liver regeneration 87
Carbon tetrachloride-
induced murine
fibrosis
HGF Hepatocytes, HSCs Hepatocyte apoptosis
inhibited, HSC trans-
differentiation to myofi-
broblasts blocked
Fibrolysis, liver
regeneration
63,74
Hepatitis C fibrosis PDGF-b HSCs HSC trans-differentiation
to myofibroblasts
Liver fibrosis 77,79,80
Carbon tetrachloride- and
thioacetamide-induced
murine fibrosis
CXCL-4 HSCs HSC chemotaxis, chemo-
kine expression, and
immune cell
recruitment
Liver fibrosis 81
Viral hepatitis Serotonin Sinusoidal circulation Delayed viral clearance,
enhanced T-cell
toxicity
Liver inflammation,
fibrosis, and cancer
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all associated with neutrophil recruitment. The molec-
ular and cellular mechanics of neutrophil recruitment
to sites of liver injury involve speciﬁc chemokines and
activation through damage-associated molecular pat-
terns.(30) Platelets not only activate and recruit neutro-
phils to inﬂamed tissue(31) but also interact with
neutrophils to trap microbes in neutrophil extracellular
traps,(32) a process known to promote neutrophil-
mediated hepatotoxicity. Researchers note enhanced
platelet-neutrophil interaction within liver sinusoids
during endotoxemia(33) and have hypothesized that
circulating platelet:neutrophil aggregates can perpetu-
ate neutrophil activation, thus driving end organ dam-
age in patients with cirrhosis.(34)
Although the accepted paradigm is that, regardless
of initial insult, neutrophils recruited to the site of liver
damage exacerbate liver damage,(24) recent evidence
suggests that they may also have anti-inﬂammatory
and restorative properties. For example, platelets have
recently been shown to physically “pave the way” for
neutrophils to enter the liver during sterile liver injury
to aid repair (Table 1).(35)
Macrophages are involved in both driving and help-
ing resolve liver disease, being capable of mediating
liver injury, ﬁbrosis progression, ﬁbrosis resolu-
tion,(36,37) pathogen clearance, and regulation of
inﬂammation.(22) Distinct macrophage subsets are
activated and recruited by factors expressed in the
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FIG. 1. (A,B) Activated platelets bind to the endothelium, causing the endothelium to up-regulate and secrete CXCL8 and CCL2.
These chemokines recruit T cells and neutrophils to the endothelium. (C) T cells use the platelets to bind to the endothelium. Plate-
lets use CD44 to bind sinusoidal hyaluronic acid, allowing T cells to survey the liver for viral antigen.
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injured liver and help shape the nature and outcome of
liver injury. Platelets have an important role in regulat-
ing these processes; platelet-derived CXCL4 and
microparticles induce patterns of macrophage activa-
tion consistent with tissue repair(38) and matrilysis,(39)
respectively. In vitro studies using human cells demon-
strated the ability of platelet-derived CXCL4 to induce
differentiation of blood monocytes to tissue macro-
phages.(40) These macrophages then switch to a proin-
ﬂammatory phenotype on interacting with activated
platelets at sites of tissue inﬂammation.(41) In the liver,
Kupffer cell-platelet interactions are important deter-
minants of the outcome in ischemia-reperfusion injury.
During the early period of an ischemic insult, platelets
sequester in the liver, with most adhering to Kupffer
cells,(42) most likely through the interactions between
platelet CLEC-2 and macrophage podoplanin, which
is up-regulated under inﬂammatory conditions.(43,44)
The interaction between platelets and Kupffer cells
provides bidirectional signals which together drive tis-
sue injury; reducing platelet-Kupffer cell binding amel-
iorates hepatic inﬂammation in steatotic livers of
rodents.(45) During ischemia-reperfusion injury
platelet-Kupffer cell interaction precedes and initiates
leukocyte accumulation, sinusoidal dysfunction, and
the iterative inﬂammation which eventually results in
liver failure.(46)
Disease-Speciﬁc Platelet
Contribution
VIRAL HEPATITIS: ARE
PLATELETS A PRIMARY
MEDIATOR OF VIRAL
HEPATITIS?
The generation of virus-speciﬁc T cells is an impor-
tant determinant of the outcome of viral hepatitis.
Lang et al. described how platelets aggravate viral hep-
atitis in mice through the secretion of serotonin, which
results in hepatic sinusoid microcirculation failure,
delayed viral clearance, and enhanced cytotoxic T lym-
phocyte (CTL)-mediated liver damage.(11) Several
other murine studies also demonstrate that depleting
platelets attenuates CTL-mediated liver damage(47);
platelet reconstitution is able to restore intrahepatic
T-cell accumulation and cytotoxicity. The need for
platelet activation is shown by studies in which recon-
stituting platelet-depleted mice with platelets rendered
resistant to activation by treatment with prostaglandin
E1 did not restore T cell-mediated liver damage (Table
1).(12) Platelet activation inhibitors including aspirin
and clopidogrel also reduce acute hepatic necroinﬂam-
mation and intrahepatic antigen-speciﬁc CTL accu-
mulation during murine viral hepatitis.(48-50)
Strikingly, reducing intrahepatic CTL accumulation in
mice by long-term low-dose aspirin therapy serves to
ameliorate the consequences of chronic hepatitis
including ﬁbrosis and the development of hepatocellu-
lar cancer.(13,51)
As with most physiological processes, a degree of
redundancy is observed when describing the molecular
basis of platelet and hepatic sinusoid interaction. There
are multiple mechanisms through which platelets
interact with HSECs, and blocking one route does not
totally abrogate binding. Thus, although blocking
integrins GPIIb/IIIa and aVb3 reduces platelet-
sinusoidal binding in vitro by almost 50%,(5) other
molecules such as platelet CD44 are also important. In
vivo murine experiments examining the mechanisms
of liver immunosurveillance by T cells reveal that plate-
lets adhere to sinusoidal hyaluronan by CD44 promot-
ing attachment of ﬂowing effector CD8 T cells to the
vessel wall (Fig. 1).(52)
THE PLATELETS OF
NONALCOHOLIC FATTY
LIVER DISEASE
The hepatic manifestation of the “metabolic syn-
drome” is nonalcoholic fatty liver disease
(NAFLD).(53) Platelets already have well-described
roles in the vascular complications of the metabolic
syndrome and atherosclerosis; a role for platelets in
NAFLD is also beginning to emerge. Mean platelet
volume, a surrogate marker of platelet turnover, is con-
sistently higher in patients with NAFLD(54); and there
is a direct correlation between mean platelet volume
and histological severity of hepatic inﬂammation and
ﬁbrosis.(55) In vivo murine studies support a role for
platelets in fatty liver disease.(56) These studies, how-
ever, need to be interpreted with caution as the antipla-
telet drug cilostizol, demonstrated to have the most
marked effect on reducing hepatic steatosis, inﬂamma-
tion, and ﬁbrosis in mice on high-fat/high-calorie or
choline-deﬁcient diets,(56) has numerous “nonplatelet”
effects. Data regarding antiplatelet therapy and liver
disease in humans are generally lacking, but a large
recent cross-sectional analysis suggests that regular
HEPATOLOGY, Vol. 00, No. 00, 2016 CHAUHAN ET AL.
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aspirin use may be associated with a lower prevalence
of NAFLD.(57)
DUAL ROLES FOR PLATELETS IN
CHOLESTATIC LIVER INJURY
Depletion of platelets protects against cholestasis-
induced hepatic inﬂammation and injury, suggesting
that platelet interactions within the microvasculature
may be important in cholestasis-induced liver dam-
age.(58) A variety of strategies designed to block plate-
let function have similar effects in acute murine
cholestatic injury. Rho-kinase inhibitors reduce liver
damage in bile duct ligation models of cholestasis,(59)
while platelet depletion reduces hepatic necroinﬂam-
mation in response to alpha-naphthylisothiocyanate-
mediated cholestatic liver injury. The alpha-
naphthylisothiocyanate cholestatic model further high-
lights the importance of platelet-mediated neutrophil
recruitment in driving liver damage because platelet
inhibition also markedly reduces intrahepatic neutro-
phil accumulation and hepatic inﬂammation.(60)
However, as with other injury models, the role of
platelets in cholestatic liver injury evolves with the
development of chronicity. Although perpetuating
acute inﬂammation early on, in the late stages of cho-
lestasis platelet activation is hepatoprotective. Inducing
a thrombocytopenia in mice during the latter stages of
chronic cholestasis therefore worsens liver function by
causing hepatic ﬁbrosis (Table 1).(61) Studies in
protease-activated receptor 4-deﬁcient mice suggest
that it is probably platelet activation resulting in plate-
let matrix metalloproteinase secretion and ﬁbrolysis
that underlies their observed hepatoprotective effect in
chronic cholestasis (Table 1).(62,63)
Liver Regeneration and
Fibrosis: Two Sides of the
Same Platelet?
PLATELETS DRIVE LIVER
REGENERATION AND INHIBIT
FIBROSIS
Platelets are critical regulators of liver regeneration.
After hepatic resection, platelets sequester at the resec-
tion margins and orchestrate the complex ontogenic
processes necessary for functional hepatic architecture
to develop.(64) The ﬁrst suggestion that platelets may
have a role in liver regeneration came from studies in
rats, where thrombocytosis was observed to aid liver
regeneration through hepatocyte growth factor
(HGF).(65) Subsequently, it was shown that platelets
are potent mediators of liver regeneration;
thrombopoietin-induced thrombocytosis experiments
have demonstrated improved survival in rodent models
of partial hepatectomy ordinarily lethal (e.g., 90% hep-
atectomy)(64) or situations where regeneration has been
traditionally thought of as undermined such as cirrho-
sis.(66) Additionally, thrombocytopenia inhibits liver
regeneration in partially hepatectomized mice.(14)
Platelet-mediated hepatic regeneration is dependent
on their ability to bind to sinusoidal endothelium,
interact with Kupffer cells, and traverse the space of
Disse to interact with the hepatocytes,(67) as described
below and shown schematically in Fig. 2.
In vitro studies with cultured HSECs reveal that pla-
telets promote endothelial production of interleukin-6
(IL-6) and vascular endothelial growth factor (VEGF)
through sphingosine 1-phosphate. These two proteins
simultaneously inhibit apoptosis and stimulate hepato-
cyte proliferation (Fig. 2),(68,69) thus providing impor-
tant cues in the regenerating liver.
Kupffer cells closely interact with platelets within
the hepatic sinusoids in the period after hepatectomy,
resulting in bidirectional activation.(67) This has two
consequences during hepatic regeneration. Firstly,
Kupffer cells begin producing tumor necrosis factor-a
(TNF-a) and IL-6, cytokines critical to liver regenera-
tion.(70,71) Secondly, activated platelets begin to move
through the sinusoidal endothelium, entering the space
of Disse (most likely attached to Kupffer cells) to
directly exert a promitogenic inﬂuence on hepato-
cytes.(72) Platelets release HGF, VEGF, and insulin-
like growth factor-1, which stimulate pro-proliferative
pathways critical to hepatocyte survival and differentia-
tion through phosphorylation of Akt and extracellular
signal-regulated kinases 1/2 (Table 1 and Fig. 2).(71)
The prohepatic or regenerative effects of platelets
extend to inhibiting ﬁbrosis. Thus, in parallel with
their mitogenic effect on hepatocytes, platelets sup-
press ﬁbrogenesis and initiate ﬁbrolytic pathways. The
role of platelets in reducing cholestasis-associated
ﬁbrosis in mice has been discussed above.(61,73) Human
platelets inhibit liver ﬁbrosis in severe combined
immunodeﬁciency mice by secreting HGF, which
exerts antiﬁbrotic effects by simultaneously blocking
hepatic stellate cell (HSC) activation and promoting
matrix metalloproteinase 9 expression (an enzyme
known to drive ﬁbrolysis).(63,74)
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BUT PLATELETS CAN ALSO
DRIVE FIBROSIS
Liver repair and regeneration require both pro-
proliferative and antiproliferative signals to coordinate
tissue repair. Platelets play a dual role: in addition to
their ability to suppress ﬁbrogenesis and drive hepatic
mitogenesis, under certain conditions platelets have
the potential to diminish hepatocyte regeneration and
exacerbate ﬁbrosis.(39,75)
Rodent studies reveal that platelet lysates have the
ability to drive proﬁbrotic cytokine secretion by HSCs
in vitro.(76) Human studies substantiate this ﬁnding as
human platelets contain the potently ﬁbrogenic trans-
forming growth factor-b (TGF-b) and platelet-
derived growth factor-b (PDGF-b)(4,77,78) (Fig. 2),
both of which induce HSC trans-differentiation in
vitro to ﬁbrogenic myoﬁbroblast-like cells.(4,77,79) Fur-
thermore, activated HSCs up-regulate the PDGF-b
receptor and are found in close apposition with seques-
tered sinusoidal platelets in patients with hepatitis C
cirrhosis.(80)
Another platelet-derived cytokine implicated in liver
ﬁbrosis is CXCL4. Hepatic CXCL4 levels increase
proportionately to ﬁbrotic burden, and CXCL4-/- mice
display markedly less hepatic ﬁbrosis in response to
injurious stimuli than their wild-type counterparts.(81)
Similar ﬁndings have been reported in human chronic
liver disease; patients with advanced ﬁbrosis have high
intrahepatic and serum concentrations of CXCL4.(81)
A schematic summarizing the platelet role in liver
regeneration and ﬁbrosis is shown in Fig. 2.
Little is known about the effects of portal
hypertension-induced thrombocytopenia in chronic
human liver disease. In keeping with murine stud-
ies,(61) however, the resolution of platelet count in sple-
nectomized patients improves liver function in
cirrhosis.(82)
PLATELET-DERIVED
SEROTONIN: A POISONED
CHALICE?
Platelet-derived serotonin further exempliﬁes the
complexity and diverse roles of platelets in liver
pathophysiology.
Most of the total-body serotonin is found in the
gut, speciﬁcally within the enterochromafﬁn cells and
enteric neurons.(83) Platelets tightly regulate the small
amount of free serotonin in the blood, using the sero-
tonin reuptake transporter.(84) Consequently, they con-
tain about 95% of the total plasma serotonin and have
high intracellular serotonin concentrations.
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FIG. 2. (A) Regeneration. Platelets stimulate liver regeneration by three simultaneous interactions. (1) Kupffer cells: On binding pla-
telets, Kupffer cells become activated and produce TNF-a and IL-6. (2) Hepatocytes: Platelets directly stimulate hepatocyte growth
and proliferation through HGF, insulin-like growth factor-1, and VEGF. (3) Sinusoidal endothelial cells: Activated platelets produce
sphingosine 1-phosphate, which promotes liver regeneration through phosphorylation of Akt and extracellular signal-regulated kinases
1/2. (B) Fibrosis. Platelets produce TGF-b, PDGF-b, and CXCL4 to aid conversion of hepatic stellate cells into collagen-producing
myoﬁbroblasts. Abbreviations: ERK, extracellular signal-regulated kinase; IGF-1, insulin-like growth factor 1; S-1-P, sphingosine
1-phosphate.
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Platelets mediate vasoconstriction within the hepatic
sinusoidal microcirculation using serotonin to mediate
HSECs or HSC contraction,(85) resulting in hepatic
hypoperfusion.(86) The vasoactive effects of platelet-
derived serotonin are likely to be the main contributors
to the effect seen by Lang et al.(11) in viral hepatitis
because Guidotti et al. report that serotonin is not
required for virus-speciﬁc T-cell accumulation in the
liver.(52)
In contrast to its nonspeciﬁc role in perpetuating
viral hepatitis, serotonin has a central and relatively
well-deﬁned role in liver regeneration. Platelet-derived
serotonin interacts with both hepatocytes and HSCs,
and it is the ability of serotonin to modulate the phe-
notypic plasticity of these cells that helps explain the
effects of serotonin in liver regeneration after injury.
In the early phase of murine liver injury, immedi-
ately after partial hepatectomy, an up-regulation of 5-
hydroxytryptamine (5HT) 2A and 2B messenger
RNA is observed in the liver. Antagonism of these
serotonin receptors (5HT 2A and 2B) inhibits liver
regeneration.(87) Furthermore, serotonin receptor
(5HT 2A, 2B, and 2C subtypes) antagonism using
ketanserin completely suppresses liver regeneration
after partial hepatectomy(88) in mice, and mice deﬁ-
cient in tryptophan hydroxylase (the enzyme necessary
for serotonin production) exhibit impaired liver regen-
eration.(14) Further proregenerative effects of platelet-
derived serotonin are seen in its ability to rescue small
for size livers following transplantation(87,89) and
reversing age-related liver pseudocapillarization.(90)
In the late stages of liver injury, however, HSCs par-
ticipate in termination of the regeneration process and
actually promote ﬁbrosis. At this time point, platelet-
derived serotonin interacts with HSC 5-HT 2b recep-
tors stimulating HSC TGF-b expression.(77,91) Fur-
thermore, activated HSCs assume a ﬁbrogenic
phenotype and up-regulate three subtypes of serotonin
receptor (5-HT 1B, 2A, and 2B), antagonism of which
results in HSC apoptosis aiding ﬁbrosis resolution.(92)
Overall the contribution of platelets in general and
platelet-derived serotonin speciﬁcally favors regenera-
tion or liver repair, but it is important to note that
regeneration and ﬁbrosis are both part of the repair
response to injury. The ability of platelets to inﬂuence
both processes demonstrates how pleiotropic these cells
are. Platelets are crucial for regeneration to occur, and
after acute liver injury, this is their dominant contribu-
tion. However, as liver damage approaches chronicity,
platelets participate in ﬁbrogenesis and actively block
regeneration, in part through serotonin-driven TGF-b
expression. Whether platelets provide predominantly
promitogenic or proﬁbrotic signals is determined by
the cellular and cytokine microenvironment speciﬁc to
the stage and type of liver injury.
Conclusion and Future
Directions
Platelets play a central role both in liver homeostasis
and in the response of the liver to injury. The complex-
ity of this role is becoming increasingly apparent as
advances in genomic, proteomic, and transcriptomic
analyses enable researchers to deﬁne roles for platelets
beyond hemostasis (Table 1).
Recent work suggests that aspirin reduces the risk of
liver ﬁbrosis in patients who have been transplanted for
hepatitis C.(93) Mechanistically, aspirin and clopidogrel
inhibit dense granule release, blocking serotonin
among other small molecules. These drugs also inhibit
the expression of a-granule-stored proteins that are
involved in heterotypic interactions between platelets/
leukocytes and the endothelium including P-selectin
and CD40L.(51) Reducing platelet activation alters
how immune-mediated chronic hepatitis progresses,
impacting even cancer development.(51) Modulating
the way platelets deliver serotonin to the liver sinusoid
during injury may also be open to therapeutic manipu-
lation. Given its propensity to aggravate viral hepati-
tis,(11) one would assume blocking serotonin would
beneﬁcial in chronic hepatitis. However, when studied
in the context of nonviral hepatic inﬂammation, for
example, acute liver injury due to acetaminophen toxic-
ity, serotonin deﬁciency worsens outcome,(94) possibly
through the ability of serotonin receptor 5HT 2A to
reduce TNF-a-mediated inﬂammation.(95) Serotoner-
gic agonists may therefore be of therapeutic beneﬁt
during acute nonviral liver inﬂammation, but little is
known about the effect of drugs such as selective sero-
tonin reuptake inhibitors on liver inﬂammation or
regeneration.
Given the complex and dualistic roles played by pla-
telets outlined above, the evidence for recommending
when to use antiplatelet therapy in liver disease is far
from complete. It is important that future preclinical
studies delineate the precise molecular basis of platelet
activation and the functional consequences in the con-
text of liver injury. Only by understanding the disease
and disease stage-speciﬁc platelet contribution will we
be able to design logical and safe interventions with
antiplatelet therapies. Evolving understanding of how
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platelets mediate inﬂammatory damage, modulate vas-
cular integrity, and interact with leukocytes(96,97) sug-
gests there may well be a role for antiplatelet therapy in
treating inﬂammatory and ﬁbrotic liver disease.
With the repertoire of antiplatelet therapy already
available, multiple potential avenues of novel treatment
are possible. As Friedman et al. aptly state, “Still, it is
heartening that platelets, which have always been pres-
ent in the scene of hepatic injury during disease, are
now also considered as actors in the scene.”
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